Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: Glycaemic control and plasma lipid levels

Fundamental and Clinical Pharmacology

Volumn 21, Issue SUPPL. 2, 2007, Pages 15-18

  Vergès, Bruno ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

Diabetes; Glitazones; Glycaemia; Lipids

Indexed keywords

GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ADD ON THERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; LIPIDS; THIAZOLIDINEDIONES;

EID: 36249011487     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00532.x     Document Type: Review

References (28)

1. Dormandy J.A., Charbonnel B., Eckland D.J. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet (2005) 366 1279 1289.
2. Vergès B. Clinical interest of PPARs ligands. Diabetes Metab. (2004) 30 7 12.
3. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care (2000) 23 1605 1611.
4. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., Freed M.I., Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. (2001) 86 280 288.
5. Wolffenbuttel B.H., Gomis R., Squatrito S., Jones N.P., Patwardhan R.N. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetes Med. (2000) 17 40 47.
6. Kipnes M.S., Krosnick A., Rendell M.S., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med. (2001) 111 10 17.
7. Fonseca V., Rosenstock J., Patwardhan R., Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA (2000) 283 1695 1702.
8. Einhorn D., Rendell M.S., Rosenzweig J., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin. Ther. (2000) 22 1395 1409.
9. Tran M.T., Navar M.D., Davidson M.B. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes. Diabetes Care (2006) 29 1395 1396.
10. Raskin P., Rendell M., Riddle M.C. et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care (2001) 24 2158 2159.
11. Rosenstock J., Einhorn D., Hershon K., Glazer N.B., Yu S., Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. (2002) 56 251 257.
12. Goldberg R.B., Kendall D.M., Deeg M.A. et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2005) 28 1547 1554.
13. Miyazaki Y., Mahankali A., Matsuda M. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. (2002) 87 2784 2791.
14. Iozzo P., Hallsten K., Oikonen V. et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care (2003) 26 2069 2074.
15. Hammarstedt A., Sopasakis V.R., Gogg S., Jansson P.A., Smith U. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia (2005) 48 96 104.
16. Sharma A.M., Staels B.J. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. Clin. Endocrinol. Metab. (2007) 92 386 395.
17. Bajaj M., Suraamornkul S., Piper P. et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J. Clin. Endocrinol. Metab. (2004) 89 200 206.
18. Walter H., Lubben G. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs (2005) 65 1 13.
19. Matsui J., Terauchi Y., Kubota N. et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes (2004) 53 2844 2854.
20. Trial Investigators, Gerstein H.C., Yusuf S. et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication). Lancet (2006) 368 1096 1105.
21. Charbonnel B.H., Matthews D.R., Schernthaner G., Hanefeld M., Brunetti P., on behalf of the QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet. Med. (2005) 22 399 405.
22. Kahn S.E., Haffner S.M., Heise M.A. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. (2006) 355 2427 2443.
23. Vergès B. Diabetic dyslipidaemia: insights for optimizing patient management. Curr. Med. Res. Opin. (2005) 21 (Suppl 1) S29 S40.
24. Rosenblatt S., Miskin B., Glazer N.B., Prince M.J., Robertson K.E., The Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron. Artery Dis. (2001) 12 413 423.
25. Schernthaner G., Matthews D., Charbonnel B., Hanefeld M., Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J. Clin. Endocrinol. Metab. (2004) 89 6068 6076.
26. Winkler K., Friedrich I., Baumstark M.W., Wieland H., März W. Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br. J. Diabetes Vasc. Dis. (2002) 2 143 148.
27. Betteridge D.J., Vergès B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia (2005) 48 2477 2481.
28. Derosa G., Cicero A.F., Gaddi A. et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin. Ther. (2004) 26 744 754.